Announced details
Adenovirus infection following hematopoietic stem cell transplantation. BCV is also being developed for double-stranded DNA virus infections, solid tumors and neurodegenerative diseases.
MTS Health Partners was engaged as an adviser. The relationship involves receiving advice on the selection of strategic partners for BCV.
Headquarters: New York. An investment bank specializing in healthcare that provides strategic and financial advisory services to healthcare companies. It advises on M&A, fundraising and strategic business restructuring in the life sciences and healthcare services sectors.
No impact on the consolidated earnings outlook for the fiscal year ending December 2026.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Brincidofovir (BCV) |
| Counterparty | MTS Health Partners |
| Counterparty overview | Headquarters: New York. An investment bank specializing in healthcare that provides strategic and financial advisory services to healthcare companies. It advises on M&A, fundraising and strategic business restructuring in the life sciences and healthcare services sectors. |
| Relationship with the Company | MTS Health Partners was engaged as an adviser. The relationship involves receiving advice on the selection of strategic partners for BCV. |
| Applicable area | Adenovirus infection following hematopoietic stem cell transplantation. BCV is also being developed for double-stranded DNA virus infections, solid tumors and neurodegenerative diseases. |
| Impact on Business Performance | No impact on the consolidated earnings outlook for the fiscal year ending December 2026. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To prepare for the early approval and commercialization of BCV in Europe, and achieve a stable supply and early availability of the drug through partnerships with companies that have supply capabilities for rare and intractable diseases.